Israel Launches National Psychedelic Study for PTSD Treatment
Translated & summarized from Mignews by baba
Israel's Ministry of Health has launched a national clinical trial using psychedelics like MDMA and psilocybin to treat chronic PTSD in patients resistant to traditional therapies. The study, involving hundreds of participants, aims to provide a safe, controlled alternative to unregulated black market treatments following a surge in trauma cases. Strict protocols will govern the use of these substances, which are currently only approved for research.
The story in 5 lines · by baba
- Israel's Ministry of Health approved a national clinical trial for psychedelic PTSD treatment.
- The study will focus on MDMA and psilocybin for treatment-resistant PTSD cases.
- The initiative addresses a surge in trauma diagnoses after the October 7th attacks.
- The program aims to provide safe, state-controlled psychedelic therapy.
- MDMA and psilocybin remain strictly prohibited for regular prescription use.
Israel's Ministry of Health has approved a groundbreaking national clinical trial to investigate the use of psychedelic drugs for treating chronic post-traumatic stress disorder (PTSD). The initiative is specifically designed for patients with treatment-resistant forms of the disorder who have not responded to conventional therapies.
The decision comes in response to a significant increase in PTSD diagnoses following the Hamas attack on October 7, 2023, and the subsequent military operations, which have placed immense strain on the country's psychological support systems. Tens of thousands of Israelis have experienced severe trauma.
The research will focus on MDMA, a component of ecstasy, and psilocybin, found in hallucinogenic mushrooms. Scientific evidence suggests these substances can temporarily lower psychological defenses, aiding in neural pathway resets, but require integration with intensive psychotherapy and lifestyle changes for lasting results. The multi-year protocol will involve hundreds of participants with moderate to severe PTSD, following a structured process of psychological preparation, supervised drug administration in certified clinics, and post-session integration.
A key objective of the state-sponsored program is to prevent individuals from seeking unregulated treatments in the black market. The ministry has established strict regulations for the handling of these substances, ensuring they are dispensed from hospital pharmacies only to authorized medical personnel for supervised sessions, thereby preventing diversion and criminal risks. This controlled approach aims to avoid issues previously seen with the unregulated distribution of medical cannabis.
Currently, MDMA and psilocybin remain classified as substances for approved scientific research only, with regular prescriptions strictly prohibited in Israel. Research communities have hailed the ministry's decision as a significant step towards evidence-based, controlled future medicine.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
